The unique combination of micro-fluidics and high-throughput mass spectrometry utilized by RapidFire™ Lead Discovery enables us to rapidly develop solution-phase, functional enzyme assays using native, label-free substrates to unlock the value of otherwise intractable targets. It can be used for the direct quantification of analytes in complex reaction mixtures with typical throughput of 4-5 seconds per sample.

In this case study, RapidFire™ Lead Discovery was used to identify inhibitors of acetylcholinesterase, an enzyme with clinical importance in Alzheimer's disease. Using RapidFire™ high throughput mass spectrometry technology, we screened a small chemical library, identified several potent inhibitors, and determined their IC50 values.
Acetylcholinesterase (AChE) converts acetylcholine to choline, changing the molecular mass from 146.2 amu to 104.1 amu. We developed a conventional HPLC-MS method to purify acetylcholine substrate and choline product from the reaction buffer with a throughput of about 6 minutes per sample. Utilizing this more traditional methodology, we determined linear enzyme kinetics (0.05 - 50 mU/mL) and the substrate Km (4.9 µM). This HPLC-MS method was then adapted to the RapidFire™ uHTMS (ultra high throughput mass spectrometry) system, using final concentrations of 10 mU/mL enzyme and 2.5 µM substrate, with a throughput of 1.5 seconds per sample. (Note that throughput is assay dependent and is more typically 4 - 5 seconds per sample.)
Using the RapidFire™ HTMS method, we screened four copies of a 960-member library (Gen-Plus from Microsource) in 48 individual 96-well microtiter plates (including eight negative and eight positive controls per plate). All 4608 samples were analyzed in under 2 hours. The average conversion was 18.7% with a standard deviation of 1.6%, corresponding to a coefficient of variability of 8.6%. Of the 48 plates screened, Z' scores of >0.5 were calculated for 46 plates with an average Z' score of >0.7.
The screen identified several lead compounds with potent inhibitory activity, including the previously known AChE inhibitors: edrophonium chloride, tacrine (Cognex), and monohydroxytacrine. The 14 most potent inhibitors were selected for IC50 determinations. Six-point log dilutions starting at 10 µM were prepared in triplicate for each inhibitor. The IC50 plates were analyzed by RapidFire™ mass spectrometry using the same conditions utilized in the primary screen with the same throughput.


|
 |
|